Roche prepares and tests new LpxH inhibitors for the treatment of bacterial infections
May 24, 2023
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified piperazinylsulfonylaryl compounds acting as UDP-2,3-diacylglucosamine hydrolase (LpxH) (bacterial) inhibitors.